What Does Elevated Troponin Mean in COVID-19?

Allan Jaffe

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Cardio-Renal Syndrome Management: What Are the Key Factors That Impa…

Patricia Kao

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

APOL1 Controversies Conference Plenary: APOL1 Pathophysiology

KDIGO

D. Friedman

EADV 2024 Insights: Calciphylaxis

EADV 2024 Insights

C. Erfurt-Berge

Benefits of Slowing the Heart with Ivabradine

San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians

Cancer Before Solid Organ Transplant

Fred Hutchinson Cancer Center

C. Blosser

KDIGO Scientific Symposium on the Impact of Viral Infection and the …

KDIGO

S. Chadban, U. Huynh-Do, M. Jadoul, D. Kumar

Social Determinants of Health for Cardiovascular Kidney Metabolic Sy…

Kibret Enyew Belay

A New Paradigm: Rethinking Hypherphosphatemia Management

Icahn School of Medicine at Mount Sinai

D. Spiegel

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim